<?xml version="1.0" encoding="UTF-8"?>
<abstract id="embj2020106057-abs-0001">
 <title>Abstract</title>
 <p>Coronavirus disease 2019 (
  <styled-content style="fixed-case" toggle="no">COVID</styled-content>‐19) is caused by 
  <styled-content style="fixed-case" toggle="no">SARS</styled-content>‐CoV‐2 and has spread across the globe. 
  <styled-content style="fixed-case" toggle="no">SARS</styled-content>‐CoV‐2 is a highly infectious virus with no vaccine or antiviral therapy available to control the pandemic; therefore, it is crucial to understand the mechanisms of viral pathogenesis and the host immune responses to 
  <styled-content style="fixed-case" toggle="no">SARS</styled-content>‐CoV‐2. 
  <styled-content style="fixed-case" toggle="no">SARS</styled-content>‐CoV‐2 is a new member of the betacoronavirus genus like other closely related viruses including 
  <styled-content style="fixed-case" toggle="no">SARS</styled-content>‐CoV and Middle East respiratory syndrome coronavirus (
  <styled-content style="fixed-case" toggle="no">MERS</styled-content>‐CoV). Both 
  <styled-content style="fixed-case" toggle="no">SARS</styled-content>‐CoV and 
  <styled-content style="fixed-case" toggle="no">MERS</styled-content>‐CoV have caused serious outbreaks and epidemics in the past eighteen years. Here, we report that one of the interferon‐stimulated genes (
  <styled-content style="fixed-case" toggle="no">ISG</styled-content>s), cholesterol 25‐hydroxylase (
  <italic>
   <styled-content style="fixed-case" toggle="no">CH</styled-content>25H
  </italic>), is induced by 
  <styled-content style="fixed-case" toggle="no">SARS</styled-content>‐CoV‐2 infection 
  <italic>in vitro</italic> and in 
  <styled-content style="fixed-case" toggle="no">COVID</styled-content>‐19‐infected patients. 
  <styled-content style="fixed-case" toggle="no">CH</styled-content>25H converts cholesterol to 25‐hydrocholesterol (25
  <styled-content style="fixed-case" toggle="no">HC</styled-content>) and 25
  <styled-content style="fixed-case" toggle="no">HC</styled-content> shows broad anti‐coronavirus activity by blocking membrane fusion. Furthermore, 25
  <styled-content style="fixed-case" toggle="no">HC</styled-content> inhibits 
  <styled-content style="fixed-case" toggle="no">USA</styled-content>‐
  <styled-content style="fixed-case" toggle="no">WA</styled-content>1/2020 
  <styled-content style="fixed-case" toggle="no">SARS</styled-content>‐CoV‐2 infection in lung epithelial cells and viral entry in human lung organoids. Mechanistically, 25
  <styled-content style="fixed-case" toggle="no">HC</styled-content> inhibits viral membrane fusion by activating the 
  <styled-content style="fixed-case" toggle="no">ER</styled-content>‐localized acyl‐CoA:cholesterol acyltransferase (
  <styled-content style="fixed-case" toggle="no">ACAT</styled-content>) which leads to the depletion of accessible cholesterol from the plasma membrane. Altogether, our results shed light on a potentially broad antiviral mechanism by 25
  <styled-content style="fixed-case" toggle="no">HC</styled-content> through depleting accessible cholesterol on the plasma membrane to suppress virus–cell fusion. Since 25
  <styled-content style="fixed-case" toggle="no">HC</styled-content> is a natural product with no known toxicity at effective concentrations, it provides a potential therapeutic candidate for 
  <styled-content style="fixed-case" toggle="no">COVID</styled-content>‐19 and emerging viral diseases in the future.
 </p>
</abstract>
